(Reuters) - Canadian drugmaker Aeterna Zentaris Inc AEZ.TO (AEZS.O) posted a wider first-quarter loss as finance costs soared.
Net loss widened to $11.5 million, or 11 cents per share, from $10.1 million, or 12 cents per share, a year ago.
The company said its net loss widened mainly due to higher net finance costs attributable to a change in fair value of its warrant liability.
Revenue rose 28 percent to $9.5 million due mainly to higher deliveries of Cetrotide — an in-vitro fertilization treatment to prevent premature ovulation.
The company recently canceled a licensing deal with New York-based Keryx Biopharmaceuticals Inc (KERX.O) for cancer drug perifosine, but said it would continue a late-stage trial on its own.
Aeterna Zentaris shares, which have lost more than two-thirds of their value in the past three months, closed at 56 Canadian cents on Tuesday on the Toronto Stock Exchange.
Reporting by Bhaswati Mukhopadhyay in Bangalore; Editing by Roshni Menon